ArticleBMJ global health2019
Diagnostic tests for Crimean-Congo haemorrhagic fever: a widespread tickborne disease.
Article in BMJ global health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 76 citations in OpenAlex.
- Evaluation of hematological and biochemical parameters in the differential diagnosis of Crimean-Congo hemorrhagic fever and brucellosis: insights from a large patient cohort.BMC infectious diseases · 2026Article
- Crimean-Congo Hemorrhagic Fever Virus in Africa: Epidemiological Trends, Transmission Ecology, Hotspot Heterogeneity, and Preparedness Challenges-A Narrative Review.Tropical medicine and infectious disease · 2026Review
- A review of post-exposure strategies for high-consequence viral pathogens in the laboratory.Clinical microbiology reviews · 2025Review
- Acute Hepatic Failure in Crimean-Congo Hemorrhagic Fever: A Case Report.Clinical case reports · 2025Article
- Crimean-Congo Hemorrhagic Fever Virus in Cattle and Ticks, Israel.Emerging infectious diseases · 2025Article
- Prognostic Value of Ratios of Inflammatory Markers in the Prognosis of Crimean-Congo Hemorrhagic Fever.Tropical medicine and infectious disease · 2025Article
- Crimean-Congo hemorrhagic fever: Pathogenesis, transmission and public health challenges.World journal of virology · 2025Review
- Genetic Variations in Crimean-Congo Hemorrhagic Fever Virus: Challenges for Molecular Diagnostic Assays-A Case Report.Case reports in infectious diseases · 2025Article
- Article
- Antibodies targeting the Crimean-Congo Hemorrhagic Fever Virus nucleoprotein protect via TRIM21.Nature communications · 2024Article
- Control strategies for emerging infectious diseases: Crimean-Congo hemorrhagic fever management.Health science reports · 2024Article
- Looking Beyond the Lens of Crimean-Congo Hemorrhagic Fever in Africa.Emerging infectious diseases · 2024Review
- Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges.Biological procedures online · 2024Review
- Crimean-Congo hemorrhagic fever outbreak affecting healthcare workers in Pakistan: an urgent rising concern.Annals of medicine and surgery (2012) · 2024Article
- Rapid diagnostic test: a critical need for outbreak preparedness and response for high priority pathogens.BMJ global health · 2024Review
- Crimean-Congo haemorrhagic fever virus in ticks, domestic, and wild animals.Frontiers in veterinary science · 2024Review
- Article
- The Biosafety Research Road Map: The Search for Evidence to Support Practices in the Laboratory-Crimean Congo Haemorrhagic Fever Virus and Lassa Virus.Applied biosafety : journal of the American Biological Safety Association · 2023Review
- Risk factors associated with Crimean-Congo hemorrhagic fever virus circulation among human, livestock and ticks in Mauritania through a one health retrospective study.BMC infectious diseases · 2023Article
- Seroprevalence of Crimean-Congo Hemorrhagic Fever Virus and Rift Valley Fever Virus in human population in Senegal from October to November 2020.IJID regions · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo haemorrhagic fever (CCHF) is a widespread tickborne disease that circulates in wild and domestic animal hosts, and causes severe and often fatal haemorrhagic fever in infected humans. Due to the lack of treatment options or vaccines, and a high fatality rate, CCHF virus (CCHFV) is considered a high-priority pathogen according to the WHO R&D Blueprint. Several commercial reverse transcriptase PCR (RT-PCR) and serological diagnostic assays for CCHFV are already available, including febrile agent panels to distinguish CCHFV from other viral haemorrhagic fever agents; however, the majority of international laboratories use inhouse assays. As CCHFV has numerous amplifying animal hosts, a cross-sectoral 'One Health' approach to outbreak prevention is recommended to enhance notifications and enable early warning for genetic and epidemiological shifts in the human, animal and tick populations. However, a lack of guidance for surveillance in animals, harmonisation of case identification and validated serodiagnostic kits for animal testing hinders efforts to strengthen surveillance systems. Additionally, as RT-PCR tests tend to be lineage-specific for regional circulating strains, there is a need for pan-lineage sensitive diagnostics. Adaptation of existing tests to point-of-care molecular diagnostic platforms that can be implemented in clinic or field-based settings would be of value given the potential for CCHFV outbreaks in remote or low-resource areas. Finally, improved access to clinical specimens for validation of diagnostics would help to accelerate development of new tests. These gaps should be addressed by updated target product profiles for CCHFV diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.